Compare OLP & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLP | LYEL |
|---|---|---|
| Founded | 1982 | 2018 |
| Country | United States | United States |
| Employees | N/A | 161 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 508.4M | 556.1M |
| IPO Year | 1995 | 2021 |
| Metric | OLP | LYEL |
|---|---|---|
| Price | $22.94 | $23.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $26.75 | ★ $30.60 |
| AVG Volume (30 Days) | 69.8K | ★ 74.3K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 7.85% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $82,740,000.00 | $36,000.00 |
| Revenue This Year | $11.98 | N/A |
| Revenue Next Year | $3.71 | $16,285.34 |
| P/E Ratio | $19.93 | ★ N/A |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $19.62 | $0.39 |
| 52 Week High | $25.90 | $45.00 |
| Indicator | OLP | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 59.33 | 55.08 |
| Support Level | $22.11 | $21.27 |
| Resistance Level | $23.38 | $27.30 |
| Average True Range (ATR) | 0.46 | 1.71 |
| MACD | 0.12 | 0.43 |
| Stochastic Oscillator | 91.16 | 74.68 |
One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.